This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Diabetes Mellitus  • Statistics and Research Methods  • Humanities  • Medicine and the Media  • Adverse Effects  • Alert me on articles by topic

Mike Mitka

JAMA. 2008;299(12):1413-1415.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Conflicting clinical trial findings announced through news releases and press conferences have the diabetes care community wondering about the possible dangers of aggressively lowering blood glucose below the levels recommended in current guidelines.

Contradictory findings from 2 studies that were announced through the news media have left physicians treating patients with diabetes concerned about the aggressive lowering of blood glucose to levels below those recommended in treatment guidelines.

At issue is the February 6 announcement and statement by the National Heart, Lung, and Blood Institute (NHLBI) that it was stopping an arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study involving intensive treatment aimed at lowering blood glucose to reach a glycated hemoglobin A_1c (HbA_1c) goal of less than 6%. Current guidelines from the American Diabetes Association (ADA) set the desired HbA_1c level at 7% or below. The stoppage came at the recommendation of . . . [Full Text of this Article]

OPPOSING RESULTS